Patient-Reported Symptoms Over 48  Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine

ConclusionsB/F/TAF was associated with lower prevalence of bothersome symptoms than ABC/DTG/3TC in both treatment-na ïve and virologically suppressed adults.
Source: The Patient - Patient-Centered Outcomes Research - Category: International Medicine & Public Health Source Type: research